GTx Company Profile (NASDAQ:GTXI)

About GTx (NASDAQ:GTXI)

GTx logoGTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GTXI
  • CUSIP: 40052B10
  • Web: www.gtxinc.com
Capitalization:
  • Market Cap: $54.06 million
  • Outstanding Shares: 16,041,000
Average Prices:
  • 50 Day Moving Avg: $4.45
  • 200 Day Moving Avg: $4.53
  • 52 Week Range: $3.35 - $11.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.91
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.25 per share
  • Price / Book: 2.70
Profitability:
  • EBIDTA: ($25,910,000.00)
  • Return on Equity: -177.62%
  • Return on Assets: -103.78%
Debt:
  • Current Ratio: 4.62%
  • Quick Ratio: 4.62%
Misc:
  • Average Volume: 22,290 shs.
  • Beta: 1.68
  • Short Ratio: 4.16
 

Frequently Asked Questions for GTx (NASDAQ:GTXI)

What is GTx's stock symbol?

GTx trades on the NASDAQ under the ticker symbol "GTXI."

How were GTx's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.39) EPS for the quarter. View GTx's Earnings History.

Where is GTx's stock going? Where will GTx's stock price be in 2017?

2 brokerages have issued twelve-month target prices for GTx's shares. Their forecasts range from $1.00 to $1.00. On average, they expect GTx's share price to reach $1.00 in the next twelve months. View Analyst Ratings for GTx.

Are investors shorting GTx?

GTx saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 99,877 shares, an increase of 0.9% from the April 13th total of 99,020 shares. Based on an average daily volume of 5,685 shares, the short-interest ratio is currently 17.6 days.

Who are some of GTx's key competitors?

Who owns GTx stock?

GTx's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.52%) and Geode Capital Management LLC (0.25%). Company insiders that own GTx stock include J Kenneth Glass, Marc Steven Hanover, Peak Foundation Pyramid and Robert James Wills. View Institutional Ownership Trends for GTx.

Who bought GTx stock? Who is buying GTx stock?

GTx's stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have bought GTx stock in the last two years include J Kenneth Glass, Marc Steven Hanover, Peak Foundation Pyramid and Robert James Wills. View Insider Buying and Selling for GTx.

How do I buy GTx stock?

Shares of GTx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GTx stock cost?

One share of GTx stock can currently be purchased for approximately $3.37.

Analyst Ratings

Consensus Ratings for GTx (NASDAQ:GTXI) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating
Consensus Rating:Hold (Score: 1.50)
Consensus Price Target: $1.00 (70.33% downside)

Analysts' Ratings History for GTx (NASDAQ:GTXI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017ValuEngineDowngradeSell -> Strong SellLowView Rating Details
9/9/2016Jefferies Group LLCReiterated RatingHold$1.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for GTx (NASDAQ:GTXI)
Earnings by Quarter for GTx (NASDAQ:GTXI)
Earnings History by Quarter for GTx (NASDAQ:GTXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.39)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.57)($0.44)ViewN/AView Earnings Details
11/3/2016Q3($0.05)($0.05)ViewN/AView Earnings Details
8/9/2016Q2($0.05)($0.04)ViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details
3/3/2016Q415($0.10)($0.04)ViewListenView Earnings Details
10/29/2015Q315($0.06)($0.04)ViewListenView Earnings Details
8/6/2015Q215($0.04)($0.03)ViewListenView Earnings Details
5/8/2015Q1($0.04)($0.04)ViewListenView Earnings Details
3/4/2015Q314($0.07)($0.05)ViewListenView Earnings Details
11/10/2014Q214($0.10)($0.06)ViewListenView Earnings Details
8/5/2014Q2($0.11)($0.15)ViewN/AView Earnings Details
5/8/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/4/2014Q413($0.13)($0.12)ViewListenView Earnings Details
11/12/2013Q313($0.21)($0.14)ViewListenView Earnings Details
7/19/2013Q2 2013($0.22)($0.20)ViewN/AView Earnings Details
5/3/2013Q1 2013($0.21)($0.20)ViewListenView Earnings Details
2/21/2013Q4 2012($0.21)($0.17)ViewListenView Earnings Details
11/8/2012Q312($0.17)$0.12$1.93 millionViewN/AView Earnings Details
8/8/2012($0.17)($0.17)ViewN/AView Earnings Details
5/8/2012($0.17)($0.18)ViewN/AView Earnings Details
2/21/2012($0.17)($0.17)ViewN/AView Earnings Details
11/4/2011($0.18)($0.15)ViewN/AView Earnings Details
8/9/2011($0.19)($0.21)ViewN/AView Earnings Details
5/9/2011($0.13)($0.05)ViewN/AView Earnings Details
2/24/2011($0.16)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GTx (NASDAQ:GTXI)
Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-1.16 EPS

Dividends

Dividend History for GTx (NASDAQ:GTXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GTx (NASDAQ:GTXI)
Insider Ownership Percentage: 40.60%
Institutional Ownership Percentage: 96.51%
Insider Trades by Quarter for GTx (NASDAQ:GTXI)
Institutional Ownership by Quarter for GTx (NASDAQ:GTXI)
Insider Trades by Quarter for GTx (NASDAQ:GTXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Peak Foundation PyramidMajor ShareholderBuy7,716,049$0.81$6,249,999.69View SEC Filing  
6/16/2016Robert James WillsChairmanBuy100,000$0.65$65,000.00View SEC Filing  
3/1/2016J Kenneth GlassDirectorBuy44,000$0.60$26,400.00View SEC Filing  
1/26/2016Marc Steven HanoverCEOBuy4,000$0.65$2,600.00View SEC Filing  
1/25/2016Marc Steven HanoverCEOBuy12,813$0.63$8,072.19View SEC Filing  
1/19/2016Marc Steven HanoverCEOBuy25,000$0.50$12,500.00View SEC Filing  
1/14/2016Marc Steven HanoverCEOBuy25,000$0.49$12,250.00View SEC Filing  
12/24/2015J Kenneth GlassDirectorBuy100$0.79$79.00View SEC Filing  
12/22/2015J Kenneth GlassDirectorBuy1,907$0.78$1,487.46View SEC Filing  
12/21/2015J Kenneth GlassDirectorBuy39,900$0.78$31,122.00View SEC Filing  
5/19/2015J Kenneth GlassDirectorBuy24,500$1.25$30,625.00View SEC Filing  
5/14/2015Robert James WillsChairmanBuy46,140$0.96$44,294.40View SEC Filing  
5/8/2015Henry Patton DoggrellVPBuy25,477$0.80$20,381.60View SEC Filing  
5/8/2015Robert James WillsChairmanBuy50,000$0.80$40,000.00View SEC Filing  
4/22/2015J Kenneth GlassDirectorBuy10,000$0.72$7,200.00View SEC Filing  
4/21/2015J Kenneth GlassDirectorBuy11,608$0.71$8,241.68View SEC Filing  
4/15/2015J Kenneth GlassDirectorBuy3,300$0.72$2,376.00View SEC Filing  
4/10/2015J Kenneth GlassDirectorBuy16,400$0.67$10,988.00View SEC Filing  
9/23/2014Marc Steven HanoverCEOBuy5,000$0.75$3,750.00View SEC Filing  
9/17/2014Marc Steven HanoverCEOBuy10,000$0.74$7,400.00View SEC Filing  
8/21/2014Marc Steven HanoverCEOBuy20,000$1.00$20,000.00View SEC Filing  
8/19/2014Marc Steven HanoverCEOBuy10,000$1.01$10,100.00View SEC Filing  
8/8/2014Henry Patton DoggrellVPBuy10,000$0.97$9,700.00View SEC Filing  
8/8/2014Marc Steven HanoverCEOBuy30,000$0.93$27,900.00View SEC Filing  
8/7/2014Jason T ShackelfordInsiderBuy10,000$0.92$9,200.00View SEC Filing  
8/7/2014Marc Steven HanoverCEOBuy30,000$0.92$27,600.00View SEC Filing  
6/6/2014James T DaltonVPSell72,883$1.30$94,747.90View SEC Filing  
3/21/2014Jack Schulermajor shareholderSell1,192,251$1.84$2,193,741.84View SEC Filing  
8/22/2013Jack Schulermajor shareholderBuy93,777$1.36$127,536.72View SEC Filing  
8/21/2013Jack Schulermajor shareholderBuy309,591$1.42$439,619.22View SEC Filing  
7/9/2013Mark Edward MostellerCFOSell17,000$6.99$118,830.00View SEC Filing  
1/17/2013James T DaltonVPSell20,000$5.20$104,000.00View SEC Filing  
12/14/2012Timothy R G SearDirectorBuy50,000$4.33$216,500.00View SEC Filing  
8/27/2012J Kenneth GlassDirectorBuy10,000$3.76$37,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for GTx (NASDAQ:GTXI)
Latest Headlines for GTx (NASDAQ:GTXI)
Source:
DateHeadline
bizjournals.com logoDrugmakers and biotechs increasingly view Trump as a business risk
www.bizjournals.com - May 19 at 10:06 AM
bizjournals.com logoBiotech firms increasingly view Trump as a business risk
www.bizjournals.com - May 17 at 5:34 PM
americanbankingnews.com logoGTx, Inc. (GTXI) Posts Earnings Results
www.americanbankingnews.com - May 16 at 5:10 PM
reuters.com logoBRIEF-GTX reports Q1 net loss per share of $0.39
www.reuters.com - May 16 at 11:27 AM
finance.yahoo.com logoGTx Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 11:12 AM
americanbankingnews.com logoGTx, Inc. (GTXI) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 13 at 7:32 AM
businesswire.com logoGTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society ...
www.businesswire.com - May 12 at 6:14 PM
americanbankingnews.com logoGTx, Inc. (GTXI) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 12 at 12:06 AM
finance.yahoo.com logoGTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting
finance.yahoo.com - May 11 at 6:09 PM
streetinsider.com logoGTx, Inc. (GTXI) Reports Preclinical Study Results of SARMs in DMD Models Published in Human Molecular Genetics
www.streetinsider.com - May 3 at 3:03 PM
finance.yahoo.com logoGTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics
finance.yahoo.com - May 3 at 3:03 PM
americanbankingnews.com logoGTx (GTXI) Earning Somewhat Favorable Press Coverage, Study Shows
www.americanbankingnews.com - April 29 at 9:57 PM
americanbankingnews.com logoGTx (GTXI) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 1:11 AM
americanbankingnews.com logoGTx (GTXI) Earns Daily News Impact Score of -0.04
www.americanbankingnews.com - April 23 at 3:59 PM
americanbankingnews.com logoGTx (GTXI) Getting Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 17 at 2:24 PM
finance.yahoo.com logoGTX INC /DE/ Financials
finance.yahoo.com - March 30 at 3:58 PM
americanbankingnews.com logo GTx, Inc. (GTXI) Given $7.00 Average Target Price by Brokerages
www.americanbankingnews.com - March 20 at 12:22 PM
americanbankingnews.com logoGTx, Inc. (GTXI) Issues Quarterly Earnings Results, Beats Expectations By $0.13 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
us.rd.yahoo.com logoGTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 16 at 3:56 AM
biz.yahoo.com logoQ4 2016 GTX Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 3:56 AM
baystreet.ca logoGTx (GTXI) Dips on Quarterly Loss
www.baystreet.ca - March 15 at 5:54 PM
finance.yahoo.com logoGTx reports 4Q loss
finance.yahoo.com - March 15 at 5:54 PM
reuters.com logoBRIEF-Gtx Inc qtrly loss per share $0.44
www.reuters.com - March 15 at 5:54 PM
seekingalpha.com logoGTx beats by $0.13
seekingalpha.com - March 15 at 7:32 AM
finance.yahoo.com logoGTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
finance.yahoo.com - March 7 at 11:19 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 14 at 4:46 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Other Events
us.rd.yahoo.com - December 21 at 11:30 PM
streetinsider.com logoJefferies Cuts Price Target on GTx, Inc. (GTXI) to $7 Following Enobosarm Trial Results
www.streetinsider.com - December 9 at 10:14 AM
streetinsider.com logoGTx, Inc. (GTXI) Announces Early Initial Success from Ongoing Enobosarm Phase 2 in ER+/AR+ Breast Cancer
www.streetinsider.com - December 8 at 11:14 PM
us.rd.yahoo.com logoGTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
us.rd.yahoo.com - December 8 at 10:53 AM
investopedia.com logoGTx Announces 1-For-10 Reverse Stock Split (GTXI)
www.investopedia.com - December 7 at 10:35 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statement
biz.yahoo.com - December 6 at 10:40 AM
investopedia.com logoGTx Declares 1-For-10 Reverse Stock Split (GTXI)
www.investopedia.com - December 6 at 10:40 AM
finance.yahoo.com logoGTx, Inc. Announces 1-for-10 Reverse Stock Split
finance.yahoo.com - December 5 at 11:13 AM
us.rd.yahoo.com logoEnobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
us.rd.yahoo.com - November 29 at 4:55 PM
us.rd.yahoo.com logoEnobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
us.rd.yahoo.com - November 29 at 4:55 PM
us.rd.yahoo.com logo7:04 am GTX announces that enobosarm achieved the pre-specified primary efficacy endpoint in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with ER+,AR+ breast cancer
us.rd.yahoo.com - November 29 at 4:55 PM
us.rd.yahoo.com logo7:04 am GTX announces that enobosarm achieved the pre-specified primary efficacy endpoint in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with ER+,AR+ breast cancer
us.rd.yahoo.com - November 29 at 4:55 PM
businesswire.com logoBusiness Wire Information
www.businesswire.com - November 23 at 8:00 AM
finance.yahoo.com logoGTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 23 at 8:00 AM
finance.yahoo.com logoBlog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone
finance.yahoo.com - November 17 at 8:30 AM
finance.yahoo.com logoGTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer
finance.yahoo.com - November 16 at 8:43 AM
streetinsider.com logoGTx, Inc. (GTXI) Announces Enobosarm Phase 2 Achieved Stage 1 Milestone
www.streetinsider.com - November 16 at 8:43 AM
finance.yahoo.com logoGTx Announces Webcast of Corporate Presentation at the Stifel 2016 Healthcare Conference
finance.yahoo.com - November 11 at 8:53 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 7 at 5:34 PM
finance.yahoo.com logoGTx reports 3Q loss
finance.yahoo.com - November 3 at 8:39 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - November 3 at 8:39 AM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Cond
biz.yahoo.com - October 12 at 10:22 AM
streetinsider.com logoGTx, Inc. (GTXI) Completes Stage 1 Milestone in Phase 2 Trial of Enobosarm in ER+/AR+ Breast Cancer
www.streetinsider.com - September 8 at 5:15 PM
biz.yahoo.com logoGTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - September 8 at 5:15 PM

Social

Chart

GTx (GTXI) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff